CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

GlobeNewswire Pharma
Original article

Inventiva Reports Unaudited 2026 First-Half Financial Results and Provides Corporate Update

EarningsNeutral
AI Analysis

Summary

Inventiva reported unaudited first-half 2026 financial results and provided a corporate update on its clinical-stage MASH oral therapy program.

Importance:2/10
Sentiment:
0.00
financial resultsH1 2026cash positioncorporate updateMASHoral therapy
Related Companies

Read the original article

Published by GlobeNewswire Pharma on September 28, 2026 6:00 AM

Read Original